Abstract
Two monoclonal antibodies (mAbs) designated 2A1 and 6A4 which had been shown to be directed against Pseudomonas aeruginosa outer membrane lipoprotein I were tested in cyclophosphamide treated mice for their protective ability against P. aeruginosa infection. Pretreatment of mice with either 2 mg of 2A1 or 4 mg of 6A4 in combination with lethally irradiated human leucocytes reduced the mortality after subsequent subcutaneous injection of 100 living P. aeruginosa organisms to 50% of the controls. Without leucocytes only mAb 2A1 (isotype IgG2b) showed protection (47%). Irradiated leucocytes alone without mAb did not protect the mice significantly from fatal P. aeruginosa infection.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Bacterial Outer Membrane Proteins / immunology*
-
Disease Models, Animal
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / immunology
-
Immunoglobulin G / therapeutic use*
-
Immunologic Deficiency Syndromes / blood
-
Immunologic Deficiency Syndromes / complications*
-
Immunologic Deficiency Syndromes / immunology
-
Leukocyte Count
-
Mice
-
Mice, Inbred BALB C
-
Pseudomonas Infections / etiology
-
Pseudomonas Infections / mortality
-
Pseudomonas Infections / therapy*
-
Pseudomonas aeruginosa / immunology*
-
Survival Rate
Substances
-
Antibodies, Monoclonal
-
Bacterial Outer Membrane Proteins
-
Immunoglobulin G